Corticosteroids Market: Market Size & Forecast 2026

Corticosteroids are synthetic drugs that mimic cortisol, a hormone produced by the adrenal glands, and are prescribed to reduce inflammation and suppress overactive immune systems. The global market encompasses a wide range of products including glucocorticoids and mineralocorticoids, delivered via oral, topical, injectable, and inhalable routes. Private market research estimates place the 2025 global market size in the range of $5.89 billion to $8.21 billion, with most studies converging around $6 billion to $6.5 billion.

• •Market encompasses multiple drug classes and delivery formats including tablets, creams, injections, and inhalers
• •Private research firms publish size estimates, but no government or statistical agency releases official global market figures
• •Widely used across therapeutic areas including dermatology, respiratory medicine, rheumatology, and gastroenterology

The primary force behind market expansion is the rising global prevalence of chronic inflammatory and autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, asthma, and skin disorders. An aging global population contributes significantly, as older adults face higher rates of conditions requiring corticosteroid therapy. Additionally, increasing healthcare access in emerging markets and the development of improved formulations with reduced side effects are supporting adoption.

• •Growing burden of autoimmune and inflammatory diseases globally
• •Aging demographics driving increased prevalence of chronic conditions requiring anti-inflammatory treatment
• •Expanding healthcare infrastructure and access in Asia-Pacific, Latin America, and other emerging regions

The market is commonly segmented by product type (glucocorticoids versus mineralocorticoids), route of administration (topical, oral, injectable, inhalation), and therapeutic application. North America and Europe currently represent the largest regional markets due to high disease prevalence, advanced healthcare systems, and strong pharmaceutical presence. The Asia-Pacific region is expected to grow at the fastest pace, fueled by rising healthcare spending, improving diagnosis rates, and growing domestic pharmaceutical manufacturing capacity.

• •Glucocorticoids represent the dominant product segment, while topical formulations account for significant revenue share
• •North America leads in market value, with Europe following closely behind
• •Asia-Pacific projected as the fastest-growing region due to expanding patient populations and healthcare investment

What are the recent trends and outlook?

Looking forward, the market is expected to continue its steady growth trajectory through 2031 and beyond, with projections varying by research firm but generally pointing to a market approaching or exceeding $8 billion. Key trends include development of novel drug delivery systems to improve patient compliance and reduce systemic side effects, as well as growing interest in combination therapies. Regulatory scrutiny around long-term corticosteroid use and safety profiles may influence prescribing patterns and product development priorities in coming years.

• •Market projected to reach approximately $8 billion to $8.5 billion by 2031 across major research estimates
• •Development focus on targeted delivery systems and reduced-side-effect formulations to improve therapeutic profiles
• •Increasing awareness of long-term safety concerns may shift usage patterns and drive innovation in alternative treatments